Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018 , at 9:00 a.m.
Toggle Summary Veracyte Announces Publication of Data Demonstrating “Real World” Performance of Afirma GSC in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 8, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of “real world” data showing that the Afirma® Genomic Sequencing Classifier (GSC) enables even more patients to avoid unnecessary surgery in thyroid cancer diagnosis compared


Date Event Details
Summary Toggle Sep 8, 2016 11:00 AM EDT
Veracyte Percepta Medicare Coverage Conference Call
Summary Toggle Nov 29, 2016 3:30 PM EST
Piper Jaffray 28th Annual Healthcare Conference


Title Documents

Canaccord Genuity Medical Technologies & Diagnostics Forum